Free Trial
NASDAQ:PTCT

PTC Therapeutics (PTCT) Stock Price, News & Analysis

PTC Therapeutics logo
$66.80 +0.28 (+0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$66.70 -0.10 (-0.15%)
As of 06:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PTC Therapeutics Stock (NASDAQ:PTCT)

Advanced

Key Stats

Today's Range
$66.09
$67.50
50-Day Range
$48.82
$68.51
52-Week Range
$35.95
$69.48
Volume
503,182 shs
Average Volume
1.15 million shs
Market Capitalization
$5.31 billion
P/E Ratio
9.58
Dividend Yield
N/A
Price Target
$69.00
Consensus Rating
Moderate Buy

Company Overview

PTC Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
65th Percentile Overall Score

PTCT MarketRank™: 

PTC Therapeutics scored higher than 65% of companies evaluated by MarketBeat, and ranked 346th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PTC Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.53, and is based on 9 buy ratings, 5 hold ratings, and 1 sell rating.

  • Upside/Downside

    The consensus price target for PTC Therapeutics is close to its current price, suggesting limited near-term upside or downside.

  • Amount of Analyst Coverage

    PTC Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about PTC Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for PTC Therapeutics are expected to decrease in the coming year, from ($4.52) to ($4.69) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PTC Therapeutics is 9.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PTC Therapeutics is 9.58, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.11.

  • Read more about PTC Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    8.99% of the outstanding shares of PTC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently decreased by 2.06%, indicating that investor sentiment is improving.
  • Dividend Yield

    PTC Therapeutics does not currently pay a dividend.

  • Dividend Growth

    PTC Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.99% of the outstanding shares of PTC Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    PTC Therapeutics has a short interest ratio ("days to cover") of 5.6.
  • Change versus previous month

    Short interest in PTC Therapeutics has recently decreased by 2.06%, indicating that investor sentiment is improving.
  • News Sentiment

    PTC Therapeutics has a news sentiment score of -0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for PTC Therapeutics this week, compared to 10 articles on an average week.
  • Search Interest

    8 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,467,670.00 in company stock.

  • Percentage Held by Insiders

    Only 5.50% of the stock of PTC Therapeutics is held by insiders.

  • Read more about PTC Therapeutics' insider trading history.
Receive PTCT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PTCT Stock News Headlines

Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
Leerink Partnrs Has Pessimistic Outlook of PTCT Q1 Earnings
See More Headlines

PTCT Stock Analysis - Frequently Asked Questions

PTC Therapeutics' stock was trading at $45.14 on January 1st, 2025. Since then, PTCT shares have increased by 48.0% and is now trading at $66.80.

PTC Therapeutics, Inc. (NASDAQ:PTCT) announced its quarterly earnings data on Thursday, August, 7th. The biopharmaceutical company reported ($0.83) earnings per share for the quarter, beating analysts' consensus estimates of ($1.07) by $0.24. The business's revenue was down 4.2% compared to the same quarter last year.
Read the conference call transcript
.

Top institutional investors of PTC Therapeutics include Pacer Advisors Inc. (0.63%), Voya Investment Management LLC (0.36%), SG Americas Securities LLC (0.16%) and Assenagon Asset Management S.A. (0.14%). Insiders that own company stock include Matthew B Klein, Stuart Walter Peltz, Michael Schmertzler, Mark Elliott Boulding, Neil Gregory Almstead, Lee Scott Golden, Eric Pauwels, Pierre Gravier, Christine Marie Utter, Emily Luisa Hill, Allan Steven Jacobson, David P Southwell, Jerome B Zeldis, Emma Reeve, Alethia Young and Stephanie Okey.
View institutional ownership trends
.

Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PTC Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and Home Depot (HD).

Company Calendar

Last Earnings
8/07/2025
Today
10/23/2025
Next Earnings (Estimated)
11/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PTCT
CIK
1070081
Employees
1,410
Year Founded
1998

Price Target and Rating

High Price Target
$118.00
Low Price Target
$42.00
Potential Upside/Downside
+3.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
15 Analysts

Profitability

EPS (Trailing Twelve Months)
$6.97
Trailing P/E Ratio
9.58
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$363.30 million
Net Margins
35.65%
Pretax Margin
37.74%
Return on Equity
-106.31%
Return on Assets
30.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.62
Quick Ratio
3.57

Sales & Book Value

Annual Sales
$806.78 million
Price / Sales
6.58
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($14.24) per share
Price / Book
-4.69

Miscellaneous

Outstanding Shares
79,440,000
Free Float
75,069,000
Market Cap
$5.31 billion
Optionable
Optionable
Beta
0.55

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:PTCT) was last updated on 10/23/2025 by MarketBeat.com Staff
From Our Partners